How to Buy Procept Biorobotics Stock
Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology.
Procept Biorobotics stock last closed at $38.00, up 2.32% from the previous day, and has decreased 53.65% in one year. It has underperformed other stocks in the Medical Devices industry by 0.2 percentage points. Procept Biorobotics stock is currently +2.98% from its 52-week low of $36.90, and -63.39% from its 52-week high of $103.81.
There are currently 55.64M shares of PRCT outstanding. The market capitalization of PRCT is $2.11B. In the last 24 hours, 1.05M PRCT shares were traded.
How to Buy Procept Biorobotics Stock
Wondering how to invest in Procept Biorobotics stock? Here's how.
- Figure out where to buy Procept Biorobotics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you figure out where to buy Procept Biorobotics stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Put funds into your brokerage account: Pick your payment method and add your details.
- Evaluate Procept Biorobotics stock: The Procept Biorobotics ticker symbol is PRCT. Is Procept Biorobotics stock a good investment? Should you buy shares of PRCT? How do PRCT's underlying business fundamentals look? Do top analysts think Procept Biorobotics is a good buy? Why has PRCT's stock price moved recently? (Hint: Our stock market research tools can help you figure out if PRCT is a good stock to buy).
- Place your PRCT trade: Decide if you will purchase PRCT shares at the current market price or use a limit order to buy PRCT shares at a particular price.
- Get key alerts regarding your PRCT investment: Create a watchlist to get the latest news on your investment in Procept Biorobotics stock.
Step 1: Figure out where to buy Procept Biorobotics stock
You will need an online brokerage account in order to access the NASDAQ market and buy PRCT stock.
Our preferred brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world financial markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've selected the best brokerage, you need to fill out some personal details so you can buy PRCT today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open a new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've created your account on the best stock trading app, you can securely and quickly fund your account:
Watch this video walkthrough if you need help transferring money into your new brokerage account.
Step 4: Evaluate Procept Biorobotics stock
After you have identified the best place to buy Procept Biorobotics stock, it's very important to analyze their stock before you buy, so you truly comprehend the risk as well as the upside.
Overview of key PRCT info
Fundamentals of Procept Biorobotics
WallStreetZen was built to help average investors perform more accurate fundamental analysis quickly.
You can see all of the due diligence checks on PRCT's stock page.
Is PRCT stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge PRCT's intrinsic value.
Using relative valuations measures:
- PRCT could be overvalued based on its P/B ratio of 5.48x, relative to Medical Devices industry P/B ratio of 3.97x
You can access additional valuation research on PRCT's stock here.
PRCT Financials at a glance
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the PRCT balance sheet.
- There are more short-term assets than short-term liabilities on the PRCT balance sheet.
- PRCT has cash burn of 89272000. It has enough cash and short-term investments to cover this for at least one year.
- PRCT has a low debt to equity ratio of 0.33.
- PRCT has $302.72M in cash and short term investments. This is enough to cover its annual cash burn of $89.27M.
Failed Financial Due Diligence Checks:
- PRCT profit margin has gone up by 0.28 percentage points in the past year, but the company is still unprofitable.
Do analysts think it's a good time to buy PRCT stock
Out of 6 Equities analysts who give forecasts on PRCT, the consensus analyst rating on PRCT is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Latest PRCT Analyst Ratings
Richard Newitter, a top 10% analyst from Truist Securities maintains PRCT with a strong buy rating and lowers their PRCT price target from $90.00 to $70.00, on Apr 11, 2025.
You can dig deeper into what analysts are forecasting on the Procept Biorobotics stock forecast page.
Metrics for Advanced PRCT Traders
PRCT Performance Numbers
Last year, PRCT revenue was $274.95M. During the past 4 year, PRCT's revenue has grown by 90.23% per year. This was faster than the Medical Devices industry average of 10.44%.
Learn more about PRCT's earnings and revenue performance here.
Latest Insiders Trades at PRCT
Over the last year, executives and large shareholders at PRCT have sold more shares than they have bought.
Antal Rohit Desai, Director of PRCT, was the latest PRCT insider to buy. They bought $35,576.17 worth of PRCT shares on Aug 14, 2025.
Research more about who owns PRCT stock here.
Does PRCT provide a stable income stream?
No, Procept Biorobotics doesn't provide an income stream by paying out dividends.
PRCT Social Trading Data
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Place your PRCT trade
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly fine. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a particular price, use a limit order.
Hit the Open Trade button and eToro will execute the order.
If you need more assistance buying stocks on eToro, watch the helpful video below:
Step 6: Get key alerts regarding your PRCT investment
Now that you own some shares in PRCT, you'll want to keep up with your shares.
Add PRCT to a watchlist to keep tabs on your PRCT stock.
PRCT Feed
How to Buy Stock in Procept Biorobotics
To reiterate, here are the 6 steps to buy stock in Procept Biorobotics:
- Figure out where to buy Procept Biorobotics stock
- Sign up for a brokerage account
- Put funds into your brokerage account
- Evaluate Procept Biorobotics stock
- Place your PRCT trade
- Get key alerts regarding your PRCT investment
If you are looking for a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you want to monitor your investment in Procept Biorobotics, click below.
Other "How To" Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.